2025 Addiction Toxicology Case Conference Webinar Series – Full Year Registration Package
-
Register
- Non-member - Tier I - Free!
- Non-member - Tier II - Free!
- Non-member - Tier III - Free!
- Non-member - Tier IV - Free!
- Member - Tier I - Free!
- Member - Tier II - Free!
- Member - Tier III - Free!
- Member - Tier IV - Free!
2025 ACMT/ASAM Addiction Toxicology Case Conference Webinar Series
Register for the entire year with just one easy click!
Typically held every month on Fridays at 1 pm ET, these webinars bring together experts in addiction medicine, psychiatry, and medical toxicology to analyze real-world addiction toxicology cases, providing valuable insights and fostering dynamic discussions through live Q&A sessions. Here’s what we've got on the calendar for 2025:
- January 10, 2025: Benzodiazepine Tapering & Discontinuation Discussion
- February 14, 2025: Driving Impairment and Medical Legal Issues
- March 7, 2025: Acute Toxic Emergencies Related to Cannabis and Marijuana Products
- May 2, 2025: Pain and Addiction
- June 6, 2025: Pediatric Emergencies from Cannabinoid Exposure
- July 11, 2025: Cancelled
- August 1, 2025: Decriminalization of Drugs
- September 5, 2025: Addiction in Older Adults
- October 3, 2025: Topic TBA
- November 7, 2025: Topic TBA
- December 5, 2025: Topic TBA
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses are available for each webinar. Check each webinar's registration page for more details. Interested in bulk buying credits for the entire year? Buy the full year's CE package and get 1 month free!
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
These webinars are open to the public.
-
Contains 5 Component(s)
Benzodiazepine Tapering & Discontinuation Discussion
Benzodiazepine Tapering & Discontinuation Discussion
Friday, January 10, 2025
1:00-2:00pm ETCase 1: Novel Synthetic Benzodiazepine Overdose
Case 2: Elderly Patient on Diazepam Presents with Acute Psychosis and Delerium
Learning Objectives
1. Demonstrate knowledge of benzodiazepine tapering and discontinuation discussions.
2. Describe the risks associated with long-term benzodiazepine use.
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Maryann Amirshahi, PharmD, MD, MPH, PhD, FACMT
Emergency Medicine Attending Physician, Professor Of Emergency Medicine
MedStar Washington Hospital Center, Georgetown University Hospital
Dr. Maryann Amirshahi is a Professor of Emergency Medicine at Georgetown University School of Medicine and practices clinically at MedStar Washington Hospital Center, where she specializes in toxicology, addiction care, and emergency medicine. She holds a PharmD and medical degree, alongside an MPH focusing on environmental and occupational health, and a PhD in pharmacology and public health. Dr. Amirshahi is board-certified in emergency medicine, medical toxicology, addiction medicine, and clinical pharmacology, and is a registered pharmacist with over a decade of practice. Nationally recognized, she serves on the Board of Directors for the American College of Medical Toxicology. With nearly 200 peer-reviewed publications, her research spans medication safety, drug shortages, addiction treatment, and prescription drug misuse.
Maureen Boyle, PhD
Chief Quality and Science Officer
American Society of Addiction Medicine (ASAM)
Maureen Boyle, PhD, is the Chief Quality and Science Officer at the American Society of Addiction Medicine (ASAM), where she oversees the development of clinical guidelines and tools to support the implementation of evidence-based practices in addiction treatment. She provides strategic leadership for the ASAM Criteria Suite of products, including ASAM CONTINUUM, the ASAM Level of Care Certification Program, and the ASAM Criteria textbook. With over 20 years of experience in research, public health, and policy, Dr. Boyle has held key leadership roles at the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Drug Abuse (NIDA). She earned her Ph.D. in Neuroscience from the Washington University School of Medicine, completed a postdoctoral fellowship at the Allen Institute for Brain Science, and is an alumna of the AAAS Science and Technology Policy Fellowship.
Emily Brunner, MD, DFASAM
Physician TTA Consultant
Hazelden Betty Ford Foundation
Dr. Emily Brunner is a board-certified family medicine physician and distinguished fellow in addiction medicine, specializing in trauma-informed, compassionate care for substance use disorders. She serves as Medical Director of Gateway Recovery and Recovering Hope and conducts trainings for the Hazelden Betty Ford Foundation. A recognized leader, she has held positions with the Minnesota Society of Addiction Medicine and currently serves on the national board of the American Society of Addiction Medicine. Dr. Brunner is a passionate advocate for expanding access to medications for opioid use disorder and improving care for patients with substance use disorders across the healthcare system. Named a Top Doctor in addiction medicine by Minnesota Magazine in 2020 and 2021, she also has a clinical interest in internet gaming and gambling disorders.
Alex Krotulski, PhD
Associate Director of Toxicology & Chemistry
The Center for Forensic Science Research and Education
Dr. Alex J. Krotulski serves as a Director at the Center for Forensic Science Research and Education (CFSRE) working in the areas of forensic toxicology and forensic chemistry and is the Program Manager for NPS Discovery, the CFSRE’s drug early warning system and flagship program for the identification and characterization of new and emerging synthetic drugs. Dr. Krotulski is a chemist by training and practices as a forensic toxicologist. Dr. Krotulski holds faculty appointment and serves as the Program Director for the Thomas Jefferson University Master of Science in Forensic Toxicology (MSFT) program and is an Senior Associate Editor for the Journal of Analytical Toxicology.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.
Maryann Amirshahi, MD, PharmD, PhD, Faculty: has nothing to disclose
Maureen Boyle, PhD, Faculty: has nothing to disclose
Emily Brunner, MD, Faculty: has nothing to disclose
Alex Krotulski, PhD, Faculty: has nothing to discloseACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
Learner Notifications:
-
Contains 4 Component(s)
Driving Impairment and Medical Legal Issues
Driving Impairment and Medical Legal Issues
Friday, February 14, 2025
1:00-2:00pm ETCase 1: Impairment vs. Impaired Field Testing
Case 2: Am I Going Too Slow or Too Fast? Cannabis in Driving
Learning Objectives
- Identify the pharmacological effects of alcohol, cannabis, opioids, and other drugs on driving ability.
- Promote harm reduction and effective patient counseling approaches.
- Evaluate the reliability and relevance of blood, urine, and breath testing in determining impairment at the time of driving.
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Jeffrey Brent, MD, PhD, FACMT
Distinguished Clinical Professor of Medicine (Pulmonary and Critical Care) and Emergency Medicine
University of Colorado School of Medicine and Public Health
Jeffrey Brent, MD, PhD, is a Distinguished Clinical Professor of Medicine (Pulmonary and Critical Care Medicine) and Emergency Medicine at the University of Colorado Schools of Medicine and Public Health. He did his fellowship in medical toxicology at the Rocky Mountain Poison and Drug Center, where he has been both medical director and fellowship director. He is a former President of the American Academy of Clinical Toxicology and a former Board member of the American College of Medical Toxicology. Dr. Brent is the senior editor of Critical Care Toxicology: the Diagnosis and Management of the Critically Poisoned Patient, currently in its second edition. Dr. Brent is Co-Principal Investigator of ACMT’s Toxicology Investigators Consortium.
Barry Logan, PhD, F-ABFT
Executive Director, Sr. VP & Chief Scientist Forensic Sciences
Center for Forensic Science Research and Education & NMS Labs
Dr. Barry Logan is the Senior Vice President of Forensic Sciences and Chief Scientist at NMS Labs, as well as the Executive Director of the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation. A Fellow of the American Board of Forensic Toxicologists (ABFT), Dr. Logan has over 190 publications exploring topics such as the effects of drugs on drivers, drug-related fatalities, and novel psychoactive substances. His current research focuses on new drug surveillance, the polydrug crisis, and the chemistry of emerging substances, leading to the founding of NPSDiscovery.org in 2018. He holds academic appointments at Indiana University, Arcadia University, and Thomas Jefferson University, and serves on the advisory board for NIDA’s National Drug Early Warning System (NDEWS). A past president of the American Academy of Forensic Sciences (AAFS), Dr. Logan was honored with TIAFT’s Alan Curry Award in 2022 for his significant contributions to forensic toxicology.
Michael G. Holland, MD, FEAPCCT, FAACT, FACOEM, FACMT, FACEP
Professor of Emergency Medicine
SUNY Upstate Medical University
Dr. Michael Holland is Clinical Professor of Emergency Medicine at SUNY Upstate Medical University in Syracuse, NY where he is on the faculty of the Medical Toxicology Fellowship Training Program and is a Consulting Medical Toxicologist at the Upstate New York Poison Center and the Onondaga County Medical Examiner’s Office-both in Syracuse, NY. Dr. Holland is also the Director of Occupational Medicine for the Saratoga Hospital Medical Group, and is the Saratoga Hospital Employee Health Medical Director, where he oversees the health and safety of over 3100 employees and staff. He also serves as Employee Health Medical Director at Glens Falls Hospital in Glens Falls, NY, covering 2500 employees. He is also Principal Medical Toxicologist at the Center for Toxicology and Environmental Health (CTEH) in Little Rock, AR.
Charles McKay, MD, FACMT
Associate Clinical Professor
University of Connecticut School of Medicine
Dr. McKay was trained in Anatomic and Surgical Pathology, Internal Medicine, Emergency Medicine, Medical Toxicology and was a Medical Director of Occupational Health and Medical Review Officer for a hospital system during more than 30 years of clinical practice, during which he provided toxicology consultation at 3 hospitals, directed a medical toxicology fellowship training program, and provided medical oversight of a regional poison control center. He provides medical legal consultation across the country on toxicology-related issues, and has testified in nearly 100 cases, many related to questions of alcohol- and drug-induced impairment.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.
Jeffrey Brent, MD, PhD Faculty: has nothing to disclose
Barry Logan, PhD, Faculty: has nothing to disclose
Michael Holland, MD, Faculty: has nothing to disclose
Charles McKay, MD, Faculty: has nothing to discloseACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
-
Contains 4 Component(s)
Acute Toxic Emergencies Related to Cannabis and Marijuana Products
Acute Toxic Emergencies Related to Cannabis and Marijuana Products
Friday, March 7, 2025
1:00-2:00pm ETCase 1: Cannabis Hyperemesis Syndrome
Case 2: Stroke Mimic: And Other Varied Presentations of Cannabis Intoxication
Learning Objectives
- Describe the diverse clinical presentations of acute cannabis intoxication, including Cannabis Hyperemesis Syndrome and other emergent conditions.
- Describe the differential diagnosis of altered mental status in the context of cannabis intoxication.
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
Hector Barreto-Vazquez, MD
Baylor College of Medicine
Andrew Monte, MD, PhD
Scientific & Medical Director, RMPDS
Drug Center & Professor of Emergency Medicine, University of Colorado
Dr. Andrew Monte is a Professor of Emergency Medicine at the University of Colorado and the Scientific & Medical Director of the Rocky Mountain Poison & Drug Safety Center. As an emergency physician and medical toxicologist, Dr. Monte’s research focuses on precision medicine and substance abuse, aiming to enhance drug safety and effectiveness in acute care settings. His work integrates clinical outcomes from electronic health records with genomic and metabolomic data to develop predictive models of drug effects. He has a particular interest in drug-drug and drug-gene interactions, as well as the public health impacts of substance use, including cannabis liberalization and illicit drug detection. Through his research, Dr. Monte seeks to improve individualized patient care by advancing our understanding of drug response variability.
David Toomey, MD
Medical Toxicology Fellow
University of Rochester Medical Center
David Toomey is a fellow in the URMC Medical Toxicology Program. He is a graduate of the Harvard Affiliated Emergency Medicine Residency and the University of Massachusetts Medical School. Prior to starting Fellowship, he was a Senior Instructor of Emergency Medicine at the University of Rochester Medical Center.
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.
Hector Barreto-Vazquez, MD, Faculty: has nothing to disclose
Andrew Monte, MD, PhD, Faculty: has nothing to disclose
David Toomey, MD, Faculty: has nothing to discloseACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
-
Contains 4 Component(s)
Pain and Addiction
Pain and Addiction
Friday, May 2, 2025
1:00-2:00pm ETCase 1: Buprenorphine in Sickle Cell Patients
Case 2: Shoulder Replacement in a Patient on Buprenorphine
Learning Objectives
- Analyze the role of buprenorphine in managing acute and chronic pain in patients with substance use disorders, including those with sickle cell disease.
- Develop evidence-based approaches to perioperative pain management for patients on buprenorphine, such as those undergoing procedures like shoulder replacement.
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
Francis Coyne, MD, FAAP, FACP
Assistant Professor of Medicine and Pediatrics
University of Rochester Medical Center
Francis Coyne is an Assistant Professor of Medicine and Pediatrics at the University of Rochester Medical Center. He developed and is currently the director of URMC’s Transition Care Medicine Fellowship Program and serves as the Director of URMC’s Inpatient Transition Program. He has built on his work and advocacy for sickle cell disease with multiple projects. He currently is the PI on a project funded by Global Blood Therapeutics that has created a care-management integrated transition initiative for children with sickle cell disease. He is also the 2021-2023 George L. Engel Dean’s Teaching Fellow, developing a curriculum to address knowledge deficits in and attitudes about sickle cell disease for emergency, family medicine, internal medicine, and medicine-pediatrics residents at URMC. Dr. Coyne is also a Co-PI on a Department of Medicine Pilot grant, working towards developing an inpatient pathway for sickle cell disease care at Strong Memorial Hospital. He is double boarded in Internal Medicine and Pediatrics, specializing in care of adults with pediatric onset conditions in clinical practice. He manages both inpatient and outpatient patients of the Complex Care Center. Dr. Coyne is enthusiastic about medical education and patient care. A large portion of his work is dedicated to the care of adults with sickle cell disease.
Rebecca D. Ellis, MD
Addiction Medicine Fellow 2024-2025, Hospice & Palliative Medicine Fellow 2023-2024
University of Pittsburgh Medical Center
Dr. Rebecca Ellis is a board certified hospice and palliative care doctor and current addiction medicine fellow at University of Pittsburgh Medical Center. She completed her residency and chief residency in internal medicine at University of Washington prior to her fellowship training. Currently, she provides primary care and palliative care services for patients living with addiction at the Internal Medicine Recovery Engagement Program (IM-REP) at UPMC. She is passionate about palliative care education and expanding access to palliative care services for patients who use drugs and alcohol. She will be joining the faculty in palliative care at URMC in 2025.
Neha Pawar, MBBS
Assistant Professor, Department of Anesthesia and Perioperative Services, Department of Psychiatry, Addiction Psychiatry
University of Rochester Medical Center
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
-
Contains 4 Component(s)
Pediatric Emergencies from Cannabinoid Exposure
Pediatric Emergencies from Cannabinoid Exposure
Friday, June 6, 2025
1:00-2:00pm ETCase 1: Pediatric Ingestion of Delta-8 Gummy
Case 2: Second-Hand Exposure
Learning Objectives
- Recognize the clinical presentations of cannabinoid intoxication in pediatric patients and discuss its implications for drug testing.
- Discuss the public health impact of environmental cannabinoid exposure, including respiratory and secondary exposures.
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
Diane Calello, MD, FACMT
Professor of Emergency Medicine; Executive and Medical Director, New Jersey Poison Information and Education System
Rutgers New Jersey Medical School
Dr. Calello, a New Jersey native and devotee, is currently the Director of Medical Toxicology at Morristown Medical Center and a toxicologist at the New Jersey Poison Information and Education System (NJPIES). She has lectured and published on various facets of clinical toxicology, particularly as it pertains to extracorporeal treatment, intravenous lipid emulsion, and poisoning in the young child. Dr. Calello received her BA from the College of William and Mary and her MD from New Jersey Medical School. She completed residency training in pediatrics, and fellowship training in both pediatric emergency medicine and medical toxicology at the Children’s Hospital of Philadelphia and Poison Control Center in Philadelphia. Dr. Calello is board certified in pediatrics, pediatric emergency medicine, medical toxicology, and addiction medicine.
Jeanna Marraffa, PHARMD, MPH, DABAT
Clinical Professor of Emergency Medicine
Upstate Medical University
Jeanna Marraffa is currently the Clinical Director of the Upstate New York Poison Center and a Clinical Professor in the Department of Emergency Medicine at Upstate Medical University, University Hospital in Syracuse, NY. She graduated from Union University, Albany College of Pharmacy with her Pharm.D. Degree in 2001 and have completed a one-year ASHP accredited Pharmacy Practice Residency at SUNY Upstate Medical University, Department of Pharmacy. She completed a 2-year Fellowship Program in Clinical Toxicology and Emergency Medicine in 2004 at the Upstate New York Poison Center, Department of Emergency Medicine at SUNY Upstate Medical University in Syracuse, NY and became a Diplomate of the American Board of Applied Toxicology in 2005. She received her Masters of Public Health in May 2020 from SUNY Albany. She has published numerous publications in the field of toxicology and have authored a book chapter in the 9th, 10th, 11th and upcoming 12th editions of Goldfrank’s Toxicologic Emergencies on “Dieting Agents”. She currently serves as president for the American Academy of Clinical Toxicology.
Donna Papsun, MS, D-ABFT-FT
Forensic Toxicologist & Business Scientist
NMS Labs
Donna Papsun is a forensic toxicologist and business scientist with NMS Labs in Horsham, PA. She has dual Bachelor of Science degrees in Chemistry and Forensic & Investigative Science and a Master of Science degree in Pharmacology. She is also certified as a Diplomate in Forensic Toxicology through the American Board of Forensic Toxicology and is a member of both the Society of Forensic Toxicologists (SOFT) and the American Academy of Forensic Sciences (AAFS).
Ms. Papsun has been with NMS Labs since 2008, first as a bench analyst before promotion to toxicologist in 2012. Ms. Papsun’s main area of interest is novel psychoactive substances or NPS. As one of the two leaders of NMS’s NPS strategy team, she continuously works to help maintain NMS’s leadership in identifying the newest trends in the changing landscape of the designer drug market and developing tests for their detection in forensic toxicology casework. Ms. Papsun also serves in a secondary role as a business scientist, working to align the technical and scientific expertise of NMS Labs with commercial efforts.
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.
Diane Callelo, MD, Faculty: has nothing to disclose.
Jeanna Marraffa, PHARMD, MPH, DABAT, Faculty: has nothing to disclose.
Donna Papsun, MS, D-ABFT-FT, Faculty: has nothing to disclose.ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
-
Contains 5 Component(s)
Decriminalization of Drugs
Decriminalization of Drugs
Friday, August 1, 2025
1:00-2:00pm ETCase 1: Navigating Palliative Care in a Contaminated Drug Supply: Fentanyl Use at End of Life
Case 2: Lessons from Lisbon: Decriminalization in Practice and Policy in Portugal
Learning Objectives
- Analyze how the presence of illicitly manufactured fentanyl has impacted the potential public health benefits of drug decriminalization efforts.
- Describe and differentiate between various models of drug decriminalization, including their legal frameworks and implementation outcomes.
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
JoAn Laes, MD, DFASAM, FACMT
Addiction Staff Physician
Abbott Northwestern Hospital, Allina Health
JoAn Laes, MD, DFASAM, FACMT is an addiction medicine physician in Minneapolis, Minnesota, focusing on inpatient addiction medicine and toxicology consultation as well as experience in outpatient treatment of opioid and other substance use disorders. She is also a core medical toxicology faculty for the Minnesota Poison Center, Minneapolis, Minnesota, and medical director for Missions Inc. Detox facility in Plymouth, Minnesota. She is board certified in Internal Medicine, Medical Toxicology, and Addiction Medicine. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.
Amber Patt, PharmD
Clinical Toxicologist
Strong Memorial Hospital
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
-
Contains 5 Component(s) Includes a Live Web Event on 09/05/2025 at 1:00 PM (EDT)
Addiction in Older Adults
Addiction in Older Adults
Friday, September 5, 2025
1:00-2:00pm ETCase 1: Managing Substance Use Disorder in a Hospitalized Patient with Limited Family Support
Case 2: Harm Reduction Strategies for an Older Adult with Cognitive Impairment and Alcohol Use Disorder
Learning Objectives
- Evaluate the challenges of providing inpatient care for individuals with substance use disorders who lack social or familial support, and explore strategies for discharge planning and care coordination.
- Apply harm reduction principles to the management of older adults with cognitive impairment and alcohol use disorder, considering safety, autonomy, and quality of life.
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
-
Contains 5 Component(s) Includes a Live Web Event on 10/03/2025 at 1:00 PM (EDT)
Topic coming soon!
This month's topic to be announced soon!
Friday, October 3, 2025
Case 1: TBA
1:00-2:00pm ETCase 2: TBA
Learning Objectives
TBA
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
-
Contains 5 Component(s) Includes a Live Web Event on 11/07/2025 at 1:00 PM (EST)
Topic coming soon!
This month's topic to be announced soon!
Friday, November 7, 2025
Case 1: TBA
1:00-2:00pm ETCase 2: TBA
Learning Objectives
TBA
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
-
Contains 5 Component(s) Includes a Live Web Event on 12/05/2025 at 1:00 PM (EST)
Topic coming soon!
This month's topic to be announced soon!
Friday, December 5, 2025
1:00-2:00pm ETCase 1: TBA
Case 2: TBA
Learning Objectives
TBA
Continuing Education
1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.
About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.
This webinar is free and open to the public.
Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)
Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center
ASAM President Elect (2025-2027)
Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.
Gloria Baciewicz, MD (Moderator)
Addiction Psychiatrist
Strong Recovery
Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.
Continuing Education
Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.Nurses
Credit being awarded: 1.25 ANCC contact hours.
Commercial Support
There is no commercial support for this activity.
Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All of the relevant financial relationships listed for these individuals have been mitigated.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.